PharmaPoint: Schizophrenia US Drug Forecast and Market Analysis to 2022

NEW YORK, April 28, 2014 /Emag.co.uk/ Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Schizophrenia US Drug Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Mental health is a major focus of the recent healthcare policy in the US. Conditions such as Alzheimers disease (AD), traumatic brain injury (TBI), PTSD, and other neurological conditions are at the forefront of current science in response to the wealth of unmet needs in both therapeutic options and overall support and care.

Scope

- Overview of Schizophrenia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the US Schizophrenia market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2012-2022 in US.

1 Table of Contents 2 Introduction 10 2.1 Catalyst 10 2.2 Related Reports 11 2.3 Upcoming Reports 12 3 Disease Overview 13 3.1 Etiology and Pathophysiology 13 3.1.1 Etiology 13 3.1.2 Pathophysiology 14 3.2 Symptoms 15

Original post:
PharmaPoint: Schizophrenia US Drug Forecast and Market Analysis to 2022